

WiT Board Candidate Profile

Sarah Meibusch GAICD

smeibusch@gmail.com

+61 409 595 408

<https://www.linkedin.com/in/sarahmeibusch>

Current Employment:

1. QAAFI Deputy Director (Queensland Alliance for Agriculture and Food Innovation - University of Queensland Research Institute); responsibility for business operations for 450 people and >\$34m p.a. operational budget and \$200m+ research under contract; 25 FTE line management
2. Asia-Pacific Business Development Consultant, Shire Pharmaceuticals (M. Cap USD \$38 B; LSX:SHR) - identify new licensing and M&A opportunities in the Australia, New Zealand, Singapore, Korea, Japan and Taiwan markets (via consulting contract)

Board & Committees Positions:

- Beartrap Solutions Pty Ltd; Director and Principal (current); international business development service; largest client Shire Pharmaceuticals (M. Cap USD \$38 B; LSX:SHR)
- Progen Pharmaceuticals (ASX:PGL; NASDAQ: PGLA); Executive Management (2003-2009); Company Secretary (2008-2009)
- Australian Voices Pty Ltd; Director (2011) – Strategic appointment to assist transition from charitable not-for-profit to a for-profit entity
- UQ-Qld Government QAAFI Agreement Steering Committee, ex officio member (2014-15) \$74+m institute over 5+ years in agriculture and food;
- TropAg2015, TropAg2017 Conference; Chair Local Organising Committee (current); 500-750 delegate science conference
- Beef CRC; Board Commercialisation Committee ex officio member (2009-2012) \$168m 7 year initiative.
- Kenmore South State School Parent and Citizens, Committee Member (current since 2013), grant writer and volunteer
- Australian Junior Simmental Association (1994-1999) National President and Queensland Committee Chair, Not for profit Association to benefit young cattle producers.
- University of Queensland Undergraduate Agriculture Society (1998) President

Professional Qualifications & Memberships:

- GAICD –Australian Institute of Company Directors – Graduate Company Director – 2015
- Harvard Business School, Executive Education Program - Negotiation and Competitive Decision Making - 2007
- Cornell University- Masters of Professional Science - 2000 -Commercialisation of science
- University of Queensland - Bachelor of Agriculture Science (Honours 1st) - 1998

Career Profile & Highlights:

- **Enterprise level business leadership** across multiple life science fields in for-profit and not-for-profit environments;
- **Strong understanding of corporate governance** – Graduate of the Australian Institute of Company Directors and hands on experience as at ASX and NASDAQ company secretary
- **International life science network**– (1500+ LinkedIn connections) across government, large & small company VP and C-level particularly agriculture and pharma
- **Strong negotiator and creative thinker** - negotiated \$34m new agreement between UQ and Qld gov. with rolling end date (2015); spearheaded the wind up of the 20 year Beef CRC (2012); led the transition of the charitable not-for-profit Australian Voices to a for-profit entity (2011); led acquisition of \$22m oncology company while at Progen (2008)
- **Driver of financial performance** – led development of new UQ QAAFI research institute (2010-current) to financially profitable position within 5 years (annual \$34m operating budget).
- **Commercialisation and Business Development** - hands-on experience in business development relationships, intellectual property development, protection, licensing, marketing and funding. As COO within the Beef CRC I led the development commercialisation plans that involve IP protection or various IP sharing/open source models depending on what is likely to have the best outcome for the stakeholders involved; As Asia Pac Business Development Consultant for Shire Pharmaceuticals I have presented >220 opportunities across Asia Pac, leading to >10 due diligence and one >\$300 m acquisition; At Progen I was part of the team that raised \$125 million over 5 capital raises and led university inlicensing endeavours, and led a \$22m company acquisition
- **Experienced in complex corporate environments** - Part of the management team that made the very tough decision to recommend Progen discontinue its Phase 3 product's \$70m clinical drug development program. This resulted in a severe impact on the company share price and attack from hedge fund attempting to liquidate the Company. The board asked me to remain with the company to manage it through this challenging time. Many of Progen's senior staff left the company and I stepped into a general management role, working alongside the CEO and the board to successfully navigate the company through corporate actions including two board spill attempts, a scheme of arrangement, an attempted hostile takeover and a share buyback scheme.